AstraZeneca PLC (AZN.L)


LSE - LSE Delayed Price. Currency in GBp
5,099.00-71.00 (-1.37%)
At close: 12:05 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open5,139.00
Prev Close5,170.00
Bid5,098.00 x 6100
Ask5,105.00 x 13000
Day's Range5,098.82 - 5,184.57
52wk Range3,680.00 - 5,505.00
1y Target EstN/A
Market Cap64.5B
P/E Ratio (ttm)29.14
BetaN/A
Volume2,059,779
Avg Vol (3m)2,741,863
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters9 hours ago

    Sanofi may win U.S. approval of $3 bln eczema drug by March

    French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March. Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition. The two companies said on Monday that the U.S. Food and Drug Administration had accepted dupilumab for priority review for treating atopic dermatitis (AD), a skin inflammation also known as atopic eczema, and set a target decision date of March 29.

  • Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
    Zacks3 days ago

    Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO

    Allergan (AGN) remained in the limelight this week thanks to its NASH-focused acquisition deals.

  • AstraZeneca Withdraws Cediranib Marketing Application in EU
    Zacks4 days ago

    AstraZeneca Withdraws Cediranib Marketing Application in EU

    AstraZeneca (AZN) announced that its decision to withdraw the Marketing Authorisation Application for cediranib in the EU.